Characterization of the resistance mechanisms of HL60 leukemia cell derivatives to Apo2L/TRAIL.

被引：0
|
作者：
Cheng, JR [1 ]
Hyladder, BL [1 ]
Baer, MR [1 ]
Repasky, EA [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.3412.3412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3412
引用
收藏
页码：931A / 931A
页数：1
相关论文
共 50 条
  • [21] TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFα but not to idarubicin and cytarabine
    Klener, Pavel
    Leahomschi, Sergiu
    Molinsky, Jan
    Simonova, Tereza
    Necas, Emanuel
    Gasova, Zdenka
    Cermak, Jaroslav
    Dolezalova, Ludmila
    Andera, Ladislav
    Zivny, Jan
    BLOOD CELLS MOLECULES AND DISEASES, 2009, 42 (01) : 77 - 84
  • [22] BORTEZOMIB TARGETS STROMA-MEDIATED APO2L/TRAIL APOPTOSIS RESISTANCE IN MULTIPLE MYELOMA
    Perez, L. E.
    Parquer, N.
    Anasetti, C.
    Dalton, W.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 65 - 66
  • [23] CHARACTERIZATION OF INSULIN-RECEPTORS IN HUMAN PROMYELOCYTIC LEUKEMIA-CELL HL60
    ABITA, JP
    GAUVILLE, C
    SAAL, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982, 106 (02) : 574 - 581
  • [24] Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
    Kamini Singh
    Arishya Sharma
    Maria C Mir
    Judith A Drazba
    Warren D Heston
    Cristina Magi-Galluzzi
    Donna Hansel
    Brian P Rubin
    Eric A Klein
    Alexandru Almasan
    Molecular Cancer, 13
  • [25] Proteomic and mRNA expression chip analysis of acquired TRAIL-resistance in human HL60 myeloid leukemia cells
    Zivny, Jail
    Klener, Pavel
    Toman, Ondrej
    Halada, Petr
    Ivanek, Robert
    Simonova, Tereza
    Andera, Ladislav
    Necas, Emanuel
    Petrak, Jiri
    BLOOD, 2007, 110 (11) : 107B - 107B
  • [26] Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2 L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance
    Ng, CP
    Zisman, A
    Bonavida, B
    PROSTATE, 2002, 53 (04): : 286 - 299
  • [27] Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL
    Cheng, Jinrong
    Hylander, Bonnie L.
    Baer, Maria R.
    Chen, Xing
    Repasky, Elizabeth A.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) : 1844 - 1853
  • [28] Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
    Mara S. Lippa
    Laura D. Strockbine
    Tiep T. Le
    Daniel G. Branstetter
    Craig A. Strathdee
    Pamela M. Holland
    Apoptosis, 2007, 12 : 1465 - 1478
  • [29] Environmental mediated-immune resistance (EM-IR) to APO2L/TRAIL mediated apoptosis
    Perez, Lia E.
    Parquet, Nancy
    Molisano, Marina
    Shain, Ken
    Alsina, Melisa
    Anasetti, Claudio
    Dalton, William
    BLOOD, 2007, 110 (11) : 1031A - 1031A
  • [30] Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma.
    Perez, Lia
    Parquet, Nancy
    Anasetti, Claudio
    Dalton, William
    BLOOD, 2008, 112 (11) : 588 - 588
12345